Want to see AU:IBX full AI Analyst Report?
IBX Stock Chart & Stats
AU$0.01
AU$0.00(0.00%)
At close: 4:00 PM EDT
AU$0.01
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.06
Previous CloseN/A
Volume1.04M
Average Volume (3M)1.31M
Market Cap
AU$4.01M
Enterprise ValueAU$7.55M
Total Cash (Recent Filing)AU$32.46K
Total Debt (Recent Filing)AU$2.19M
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Feb 26, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding801,006,900
10 Day Avg. Volume1,829,881
30 Day Avg. Volume1,314,742
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-3.21
Price to Sales (P/S)0.00
P/FCF Ratio-1.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
MagSense Molecular Imaging PlatformThe MagSense platform uses a targeted molecular-imaging approach rather than relying only on conventional anatomical scans. Its intended ability to support earlier cancer detection and disease characterization provides a differentiated long-term development direction, if clinical and commercial execution succeeds.
High Gross Margin PotentialThe approximately 85% gross margin recorded in 2024 indicates that the underlying technology could have attractive economics once commercial scale is achieved. Although current revenue and earnings are insufficient, strong gross profitability may support future operating leverage if adoption develops.
Reduced Cash OutflowThe reduction in free-cash-flow outflow during 2025 is a modest improvement in cash discipline compared with the prior year. If sustained, lower annual cash consumption could extend funding duration and provide more time to advance the MagSense platform toward commercialization.
Bears Say
No Current RevenueRevenue falling to zero in 2025 shows that the company has not yet established a dependable commercial revenue base. Without recurring sales, progress depends on successfully converting development work into products and customer adoption, leaving near-term financial self-sufficiency weak.
Negative Equity And Solvency StressPersistently negative equity materially weakens the balance sheet and reduces the cushion available to absorb continued losses. Meaningful debt alongside declining assets increases financial flexibility concerns, making future funding and capital allocation more important to sustaining operations.
Persistent Cash BurnConsistently negative operating and free cash flow confirms that the business is not funding itself through operations. The roughly 4.0M 2025 burn means ongoing external funding is required, which can constrain development plans and expose shareholders to financing-related dilution or pressure.
Imagion Biosystems Ltd. News
IBX FAQ
What was Imagion Biosystems Ltd.’s price range in the past 12 months?
Imagion Biosystems Ltd. lowest share price was AU$0.01 and its highest was AU$0.06 in the past 12 months.
What is Imagion Biosystems Ltd.’s market cap?
Imagion Biosystems Ltd.’s market cap is AU$4.01M.
When is Imagion Biosystems Ltd.’s upcoming earnings report date?
Imagion Biosystems Ltd.’s upcoming earnings report date is Feb 26, 2027 which is in 118 days.
How were Imagion Biosystems Ltd.’s earnings last quarter?
Imagion Biosystems Ltd. released its earnings results on Aug 24, 2026. The company reported -AU$0.004 earnings per share for the quarter.
Is Imagion Biosystems Ltd. overvalued?
According to Wall Street analysts Imagion Biosystems Ltd.’s price is currently Overvalued.
Does Imagion Biosystems Ltd. pay dividends?
Imagion Biosystems Ltd. does not currently pay dividends.
What is Imagion Biosystems Ltd.’s EPS estimate?
Imagion Biosystems Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Imagion Biosystems Ltd. have?
Imagion Biosystems Ltd. has 801,006,900 shares outstanding.
What happened to Imagion Biosystems Ltd.’s price movement after its last earnings report?
Imagion Biosystems Ltd. reported an EPS of -AU$0.004 in its last earnings report. Following the earnings report the stock price went up 10%.
Which hedge fund is a major shareholder of Imagion Biosystems Ltd.?
Currently, no hedge funds are holding shares in AU:IBX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Imagion Biosystems Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:IBX Sentiment 88%
Sector Average 64%
Sector Average 64%
Insider Transactions
Bought Shares
Worth AU$75.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
165.88%
Trailing 12-Months
Asset Growth
-27.94%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Imagion Biosystems Ltd.
Imagion Biosystems Limited operates as a medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases in Australia. The company is involved in nanotechnology; biotechnology; medical imaging using magnetic resonance; and cancer diagnostics businesses. It develops MagSense, which is in Phase 2 for the treatment of HER2 breast cancers, as well as advancing the research and development programs for prostate and ovarian cancer. It also develops PrecisionMRX, an iron oxide nanoparticle to magnetic relaxometry. The company has collaboration agreement with Wayne State University to develop optimised MRI sequences which is in Phase 2 study of for the MagSense imaging agent. Imagion Biosystems Limited was incorporated in 2016 and is based in Melbourne, Australia.
Technical Analysis
―
BCAL Diagnostics Limited
―
Rhythm Biosciences Ltd.
―
Genetic Signatures Ltd.
―
Integral Diagnostics Ltd.
―